reactivity. Incorporation of these olefins into the quinazoline templates produced potentEGFRinhibitors with improved safety and pharmacokinetic properties. A lead compound 5a was validated against EGFRWT, EGFRT790M as well as A431 and H1975 cancer celllines. Additionally, compound 5a displayed a weaker inhibition against the EGFR-independent cancer cell line SW620 when compared with afatinib. Oral administration
A series of novel benzothiozinone (BTZ) derivatives were designed, prepared and evaluated for antituberculosis activity. Specifically, the BTZ pharmacophore is retained and the previous heterocyclic ring linker is replaced by alkynyl or vinyl linker, the resulting compounds displayed about 5−fold improved antimycobacterial activity. We further revealed that the linker attached tail group affects the
设计、制备了一系列新型苯并噻嗪酮(BTZ)衍生物并评估其抗结核活性。具体而言,保留 BTZ 药效团,并用炔基或乙烯基连接基取代先前的杂环连接基,所得化合物显示出约 5 倍的抗分枝杆菌活性。我们进一步揭示,尾部连接基团会影响化合物的代谢稳定性、效力和其他药物特性。这项工作发现了两种具有可接受的低 MIC 和改善的代谢稳定性的化合物( A1和A11 )。代表性化合物A11在急性结核感染小鼠模型中表现出杀菌功效。
Dioxolane compounds
申请人:NEPERA CHEMICAL CO INC
公开号:US02769808A1
公开(公告)日:1956-11-06
Alkyl Ethers of Basically-substituted 2-Amino-1-phenylethanol<sup>1</sup>